Global Gene Modifying Immunotherapy for Blood Cancer Market Size, Status and Forecast 2019-2025

Published On: Nov 2019

Format: PDF

Publisher: QY Research

Pages: 96

Report ID: 68092

This report focuses on the global Gene Modifying Immunotherapy for Blood Cancer status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Gene Modifying Immunotherapy for Blood Cancer development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

The key players covered in this study
Novartis
Kite Pharma
Juno Therapeutics
Cellectis
Ziopharm Oncology
Celyad
Bluebird Bio
Bellicum Pharmaceuticals
Mustang Bio

Market segment by Type, the product can be split into
CAR T-cell Therapy
TCR T-cell Therapy

Market segment by Application, split into
Acute Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
B Cell Lymphoma
Multiple Myeloma
Other

Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
Central & South America

The study objectives of this report are:
To analyze global Gene Modifying Immunotherapy for Blood Cancer status, future forecast, growth opportunity, key market and key players.
To present the Gene Modifying Immunotherapy for Blood Cancer development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.

In this study, the years considered to estimate the market size of Gene Modifying Immunotherapy for Blood Cancer are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Table of Contents

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered
1.4 Market Analysis by Type
1.4.1 Global Gene Modifying Immunotherapy for Blood Cancer Market Size Growth Rate by Type (2014-2025)
1.4.2 CAR T-cell Therapy
1.4.3 TCR T-cell Therapy
1.5 Market by Application
1.5.1 Global Gene Modifying Immunotherapy for Blood Cancer Market Share by Application (2019-2025)
1.5.2 Acute Lymphocytic Leukemia
1.5.3 Chronic Lymphocytic Leukemia
1.5.4 B Cell Lymphoma
1.5.5 Multiple Myeloma
1.5.6 Other
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends
2.1 Gene Modifying Immunotherapy for Blood Cancer Market Size
2.2 Gene Modifying Immunotherapy for Blood Cancer Growth Trends by Regions
2.2.1 Gene Modifying Immunotherapy for Blood Cancer Market Size by Regions (2019-2025)
2.2.2 Gene Modifying Immunotherapy for Blood Cancer Market Share by Regions (2014-2019)
2.3 Industry Trends
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis

3 Market Share by Key Players
3.1 Gene Modifying Immunotherapy for Blood Cancer Market Size by by Players
3.1.1 Global Gene Modifying Immunotherapy for Blood Cancer Revenue by by Players (2014-2019)
3.1.2 Global Gene Modifying Immunotherapy for Blood Cancer Revenue Market Share by by Players (2014-2019)
3.1.3 Global Gene Modifying Immunotherapy for Blood Cancer Market Concentration Ratio (CR5 and HHI)
3.2 Gene Modifying Immunotherapy for Blood Cancer Key Players Head office and Area Served
3.3 Key Players Gene Modifying Immunotherapy for Blood Cancer Product/Solution/Service
3.4 Date of Enter into Gene Modifying Immunotherapy for Blood Cancer Market
3.5 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type and Application
4.1 Global Gene Modifying Immunotherapy for Blood Cancer Market Size by Type (2014-2019)
4.2 Global Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2014-2019)

5 North America
5.1 North America Gene Modifying Immunotherapy for Blood Cancer Market Size (2014-2019)
5.2 Gene Modifying Immunotherapy for Blood Cancer Key Players in North America
5.3 North America Gene Modifying Immunotherapy for Blood Cancer Market Size by Type
5.4 North America Gene Modifying Immunotherapy for Blood Cancer Market Size by Application

6 Europe
6.1 Europe Gene Modifying Immunotherapy for Blood Cancer Market Size (2014-2019)
6.2 Gene Modifying Immunotherapy for Blood Cancer Key Players in Europe
6.3 Europe Gene Modifying Immunotherapy for Blood Cancer Market Size by Type
6.4 Europe Gene Modifying Immunotherapy for Blood Cancer Market Size by Application

7 China
7.1 China Gene Modifying Immunotherapy for Blood Cancer Market Size (2014-2019)
7.2 Gene Modifying Immunotherapy for Blood Cancer Key Players in China
7.3 China Gene Modifying Immunotherapy for Blood Cancer Market Size by Type
7.4 China Gene Modifying Immunotherapy for Blood Cancer Market Size by Application

8 Japan
8.1 Japan Gene Modifying Immunotherapy for Blood Cancer Market Size (2014-2019)
8.2 Gene Modifying Immunotherapy for Blood Cancer Key Players in Japan
8.3 Japan Gene Modifying Immunotherapy for Blood Cancer Market Size by Type
8.4 Japan Gene Modifying Immunotherapy for Blood Cancer Market Size by Application

9 Southeast Asia
9.1 Southeast Asia Gene Modifying Immunotherapy for Blood Cancer Market Size (2014-2019)
9.2 Gene Modifying Immunotherapy for Blood Cancer Key Players in Southeast Asia
9.3 Southeast Asia Gene Modifying Immunotherapy for Blood Cancer Market Size by Type
9.4 Southeast Asia Gene Modifying Immunotherapy for Blood Cancer Market Size by Application

10 India
10.1 India Gene Modifying Immunotherapy for Blood Cancer Market Size (2014-2019)
10.2 Gene Modifying Immunotherapy for Blood Cancer Key Players in India
10.3 India Gene Modifying Immunotherapy for Blood Cancer Market Size by Type
10.4 India Gene Modifying Immunotherapy for Blood Cancer Market Size by Application

11 Central & South America
11.1 Central & South America Gene Modifying Immunotherapy for Blood Cancer Market Size (2014-2019)
11.2 Gene Modifying Immunotherapy for Blood Cancer Key Players in Central & South America
11.3 Central & South America Gene Modifying Immunotherapy for Blood Cancer Market Size by Type
11.4 Central & South America Gene Modifying Immunotherapy for Blood Cancer Market Size by Application

12 International Players Profiles
12.1 Novartis
12.1.1 Novartis Company Details
12.1.2 Company Description and Business Overview
12.1.3 Gene Modifying Immunotherapy for Blood Cancer Introduction
12.1.4 Novartis Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2014-2019))
12.1.5 Novartis Recent Development
12.2 Kite Pharma
12.2.1 Kite Pharma Company Details
12.2.2 Company Description and Business Overview
12.2.3 Gene Modifying Immunotherapy for Blood Cancer Introduction
12.2.4 Kite Pharma Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2014-2019)
12.2.5 Kite Pharma Recent Development
12.3 Juno Therapeutics
12.3.1 Juno Therapeutics Company Details
12.3.2 Company Description and Business Overview
12.3.3 Gene Modifying Immunotherapy for Blood Cancer Introduction
12.3.4 Juno Therapeutics Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2014-2019)
12.3.5 Juno Therapeutics Recent Development
12.4 Cellectis
12.4.1 Cellectis Company Details
12.4.2 Company Description and Business Overview
12.4.3 Gene Modifying Immunotherapy for Blood Cancer Introduction
12.4.4 Cellectis Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2014-2019)
12.4.5 Cellectis Recent Development
12.5 Ziopharm Oncology
12.5.1 Ziopharm Oncology Company Details
12.5.2 Company Description and Business Overview
12.5.3 Gene Modifying Immunotherapy for Blood Cancer Introduction
12.5.4 Ziopharm Oncology Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2014-2019)
12.5.5 Ziopharm Oncology Recent Development
12.6 Celyad
12.6.1 Celyad Company Details
12.6.2 Company Description and Business Overview
12.6.3 Gene Modifying Immunotherapy for Blood Cancer Introduction
12.6.4 Celyad Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2014-2019)
12.6.5 Celyad Recent Development
12.7 Bluebird Bio
12.7.1 Bluebird Bio Company Details
12.7.2 Company Description and Business Overview
12.7.3 Gene Modifying Immunotherapy for Blood Cancer Introduction
12.7.4 Bluebird Bio Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2014-2019)
12.7.5 Bluebird Bio Recent Development
12.8 Bellicum Pharmaceuticals
12.8.1 Bellicum Pharmaceuticals Company Details
12.8.2 Company Description and Business Overview
12.8.3 Gene Modifying Immunotherapy for Blood Cancer Introduction
12.8.4 Bellicum Pharmaceuticals Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2014-2019)
12.8.5 Bellicum Pharmaceuticals Recent Development
12.9 Mustang Bio
12.9.1 Mustang Bio Company Details
12.9.2 Company Description and Business Overview
12.9.3 Gene Modifying Immunotherapy for Blood Cancer Introduction
12.9.4 Mustang Bio Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2014-2019)
12.9.5 Mustang Bio Recent Development

13 Market Forecast 2019-2025
13.1 Market Size Forecast by Product (2019-2025)
13.2 Market Size Forecast by Application (2019-2025)
13.3 Market Size Forecast by Regions
13.4 North America
13.5 Europe
13.6 China
13.7 Japan
13.8 Southeast Asia
13.9 India
13.10 Central & South America

14 Analyst's Viewpoints/Conclusions

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Disclaimer
15.3 Author Details